Financing ·
CASI Pharmaceuticals reported first-half 2026 revenues of $9.8 million and a net loss of $20.0 million
CASICASI Pharmaceuticals, Inc.
CASI Pharmaceuticals reported first-half 2026 revenues of $9.8 million and a net loss of $20.0 million. The company completed a $15 million convertible note financing with ETP Global III Fund LP, controlled by Executive Chairman Dr. Wei-Wu He. Additionally, CASI entered into a settlement agreement with Acrotech Biopharma Inc., rescinding the prior termination of the EVOMELA license and keeping agreements in full force. The company also received a favorable final award in the Juventas arbitration, totaling well over RMB 100 million. Clinically, CASI dosed the first patient in its Phase 1/2 trial for CID-103 in renal allograft antibody-mediated rejection in China and completed enrollment of Part A for its ITP study. The filing notes the company's delisting from Nasdaq and subsequent quotation on OTCQB under ticker CASIF. CASI Pharmaceuticals is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.